What is Wedbush’s Estimate for Vor Biopharma Q1 Earnings?

Vor Biopharma Inc. (NYSE:VOR) – Equities research analysts at Wedbush issued their Q1 2026 EPS estimates for Vor Biopharma in a report released on Thursday, May 8th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.21) per share for the quarter. Wedbush has a “Neutral” rating and a $0.40 price objective on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($1.42) per share. Wedbush also issued estimates for Vor Biopharma’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.20) EPS.

Other analysts have also issued reports about the stock. JMP Securities reissued a “market perform” rating and set a $6.00 target price on shares of Vor Biopharma in a research note on Friday. Baird R W lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Jones Trading lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Citizens Jmp lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday. Finally, Oppenheimer reissued an “outperform” rating and set a $8.00 target price on shares of Vor Biopharma in a research note on Friday, March 21st. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Vor Biopharma presently has an average rating of “Hold” and a consensus price target of $7.06.

Vor Biopharma Stock Down 5.4%

VOR stock opened at $0.15 on Monday. The stock has a market capitalization of $18.89 million, a price-to-earnings ratio of -0.09 and a beta of -0.21. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $1.87. The firm’s fifty day simple moving average is $0.70 and its two-hundred day simple moving average is $0.97.

Institutional Trading of Vor Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at about $60,000. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after buying an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at about $707,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at about $80,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Vor Biopharma during the fourth quarter valued at about $33,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.